Acumen Pharmaceuticals Inc (ABOS) Quote

Bought more today!! Price hasn't shaken my confidence.

$2.83/ share in CASH PLUS GREAT drug completing Phase II enrollment!!

PURA VIDA!!!

ABOS, new 52/week low

One thing for certain, "Time will tell".....while still perplexed and waiting, a nice subtle encouraging comment from the CEO helps..

21 Feb 2025, Scrip Asks... What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances

“In 2025, I expect the biopharma industry to build on the strong momentum of recently approved treatments for Alzheimer’s by prioritizing the development of new Alzheimer’s therapies with improved safety profiles, particularly lower ARIA [amyloid-related imaging abnormalities, a side-effect of amyloid-beta therapies] rates,” predicted Daniel O’Connell, CEO of Acumen Pharmaceuticals.

“By focusing on novel approaches that enhance safety and broaden accessibility, there is potential to reach more patients and significantly improve their quality of life. Additionally, preferentially targeting other components of the Alzheimer’s disease pathway, such as toxic amyloid beta oligomers, offers an opportunity for next-generation therapies that can be used independently or in combination, providing greater efficacy and differentiated treatment outcomes. This progress of further innovation ensures that more patients benefit from treatments that could greatly enhance their quality of life,” O’Connell added.

BTW; I predict, there will be MANY days when this stock is UP more than it's current price in one day!!

PURA VIDA!!

Stockrafter; Great series of articles.

One day as I've said this stock has a $200 potential. That's what investing is about. Risk/Reward here is Ridiculous!!!

Keep the faith!! I pray that Sabirnitug has a MAJOR positive effect on Alzheimers disease. It will be a game changer for humanity!!

No, do not think they are going head to head, but it is in the same game, so keeping track on it, while waiting. The pic of the auto-injector was interesting. It is the same AI Biogen uses for the Plegridy Pen, fwiw.

Enough on that, check out the info below……it is eye opening information……

The beginning of the story…… https://news.northwestern.edu/stories/2019/01/a-new-approach-to-alzheimers-disease/

Developer of Sabirnetug.……smart dude…. https://neurobiology.northwestern.edu/people/core-faculty/klein-william.html

The website…check out the research and other links……good stuff…. https://kleinlab.org/

Write up on the impressive team……. https://news.weinberg.northwestern.edu/2024/01/29/neuroscientist-william-kleins-purpose-and-perseverance-continues-inspiring-a-new-wave-of-efforts-to-combat-alzheimers-disease/

“Acumen is among the foremost drug discovery companies attacking amyloid beta oligomers and its most promising therapeutic, ACU193, derives from an antibody program initiated in Klein’s research lab decades ago.”

So now even more perplexed on the share price..........but one of these days.....no doubt.......

You are making the mistake to think that Acumen's drug; Saburnitug is competing head on with Leqembi. We are in a Phase II trial to try and prove that Saburnitug is a BETTER drug AND has SIGNIFICANTLY FEWER SERIOUS side affects that Leqembi.

The action of mechanism is much different in Saburnitug!!

I understand enrollment has been rapid and I would expect to hear that full enrollment has been reached considerably before the end of the first half of 2025 which was the Company's target date.

PATIENCE IS A VIRTUE!!!

FYI; the biotech market has been weak due to the new administration and the unknowns of RFK Jr.

GLTA!!!

Well this is not helping...but it is what it is, competition doesn't wait......need info from management to reverse the relentless decline.......

"submitted applications for approval of lecanemab in 17 countries and regions. Additionally, the FDA accepted Eisai's Supplemental Biologics License (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing in January 2025 and set a PDUFA action date for August 31, 2025."

https://media-us.eisai.com/2025-01-26-FDA-Approves-LEQEMBI-R-lecanemab-irmb-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease

https://alzheimersweekly.com/leqembi-autoinjector-to-treat-alzheimers-in-seconds-not-hours/

Some interesting info from their partner on SC injection. The partner company reported signing a small volume AI deal with a company…Highly suspect it was Acumen…..It fits the timeline, since a deal needs to be signed before announcing the upcoming P2 SC trial, which will also be validating the AI SC IMO…..

Yet they can still beat the price down....so Perplexing to this small investor.......

New article on the P1 trial, more of the same but in detail....…. https://www.sciencedirect.com/science/article/pii/S2274580725000263

Interesting short video on the two current ALZ drugs….given by IV, 1x mn or 2x mn, at $25,000yr……All the more reason for SC injection in 3 seconds....…

https://www.kare11.com/article/news/health/another-treatment-those-affected-alzheimers-disease/89-d293e960-867f-4f71-9e61-91cf03d23a2a

Thanks the posts, it all sounds good, which is why it is so perplexing to me, as to who is selling all those shares over the past few months? It is easily noticeable on the Yahoo chart, that since the big drop back on 11/12/2024 the volume is relatively higher than past, and the price keeps falling. Roughly 400,000 for 40 days, is 16,000,000 shares, all below $2.50, with Yahoo Finance showing only 34 million in the float. Perplexing!

As a small investor, one can only buy so many shares, or risk a large percentage of the portfolio in one stock. Would have been nice, to have the technical skills, to surmise the SP would drop so low, certainly would have more share at a lower price. Still with an expected share price greatly exceeding my expectation of low teens, waiting will not be a problem. Unfortunately it is down today already, with high volume. Perplexing!

BTW; at the end of September there were approximately 60 million shares outstanding.

Cash and marketable securities were $207M. Let's be conservative and say that there was $170M+ at Y/E. That means there was $2.83/share in CASH equivalents at Y/E. What is their research results to date worth? What about value for getting the drug into this Phase II trial?

This Company is worth WAY IN EXCESS of where it is currently trading.


GLTA!!!

$200/share is NOT an extraordinary target!!

500,000 new AD patients in US/year. Lilly drug is $32k/year per patient = $16 BILLION/year in potential AD sales in US alone!!!

As I said yesterday the Risk/Reward is INCREDIBLE. Let the sellers sell, I'm a buyer!!!

And yes, BIG PHARMA will be foaming at the mouth to buy this Company if this trial gets positive results.

Well SotG that is some optimism, 200 bucks, I will be happy if it hits 10 bucks. I would be a millionaire at 200 bucks if I held all my shares till that happens. If sabirnetug showed some serious promise, I would suspect a larger company would buy ABOS before it reached such high price levels.

Agree there are a few drugs in progress, problem is that it appears Lilly is pushing theirs drug along fairly quickly, and they have the bucks to push thru as fast and far as they can.

The recent sells by a number of insiders, did not help, and did not look promising, no matter what their reasons.

Certainly not dropping out, will continue posting interesting news. Keep up the posting...........

From a recent article......."This trial aims to enroll approximately 540 individuals across multiple sites in the United States, Canada, the United Kingdom, and the European Union. If successful, sabirnetug could mark a significant breakthrough in neurodegenerative disease treatment."

There are MANY drugs in various stages of clinical and preclinical trials for Alzheimers disease, and there won't be just one winner. The Acumen drug Sabirnitug looks to have a better safety profile against ARIA and has a totally different target mechanism than approved drugs. The current Phase II is hoping to continue to show safety as well as efficacy!!. I'm invested here because I think this is a much better drug.

The pressure in the stock is due to a lack of news and this trial is suppose to run 18 months. I'm hoping Acumen will be in a position soon to announce that the trial is fully enrolled. Acumen is completely funded to complete this trial and does NOT need funding.

I continue to accumulate shares as I think this will be a $200 stock if the trial is successful.

It does require patience, but that is what investing is about. I think the REWARD here FAR outweighs the risk.

GLTA

Well there you go, suspect the story presented is correct, the problem appears to be the competition, its always the competition....well back to looking, holding, and hoping on Acumen.......with Lilly back in the race......

https://www.neurologylive.com/view/phase-3-trailrunner-alz-3-test-effects-igg1-monoclonal-antibody-remternetug-early-alzheimer-disease

https://www.beingpatient.com/remternetug-alzheimers-prevention-trial/

Well clearly there has to be something missing in the story Dr. Doherty presented in his enlightening informative discussion, otherwise the share price would not be on this relentless downward trend, IMO....Will continue looking, hoping, and holding, just seems the potential is there........not like I've never made a bad investment before.......

Thanks for posting that interview. VERY interesting and informative!!

Guess they sell when they need to, and can.

Some recent news out there, good, and bad, but think the discussion in the interview answers some of the bad question the whiner, Pillar mentions in his article.

The bad, nothing is perfect, always someone trying to cheat. Fix it and move on.

https://www.almendron.com/tribuna/the-devastating-legacy-of-lies-in-alzheimers-science/

A GREAT interview, every investor, needs to listen to.....things start around 11 minutes, 25 minutes, and 28 minutes in..updates on trials towards end of interview....



The clinical trial...

https://clinicaltrials.eu/trial/study-on-the-effects-of-sabirnetug-for-patients-with-early-alzheimers-disease/

,

Another batch of insider sales today that were the result of the exercise of stock options that were granted as compensation. Hopefully this is the end!! I have been impressed that all shares are being accumulated when for sale.

Yes, volume has been increasing these past few days/weeks, sadly the price is not doing the same.. Just a relentless downward trend, With only 32 million or so in the float, one would think the SP would start increasing with the increasing volume. Been looking new info but nothing pops up. Most are waiting for updates on clinical trials. But will hang in there, keep up the effort.....

powerful trading today! Over 500,000 shares of upside volume. Real sign of life!!

IMO; Some institution has been accumulating shares. Now that selling is drying up, I would expect a steady move upward.

Insider sales today of a total of 26,534 shares was the result of vesting of stock options. IMO; this should be the end of insider sales.

Next news from this Company should be very positive.

HUGE VOLUME is HUGE today; obviously finally cleaned up seller!!

Company has stated they expect to reach full enrollment of PII in the first half of 2025. I predict they will reach full enrollment in this study by the end of Q1.

PURA VIDA!!

Good PR, not much new, but still a good PR. Waiting for update on full enrollment of the Phase II/III Safety & Efficacy trial, an update on the completed P1 SC trial and plans for the P2 SC, which IMO will be using a HALO autoinjector.

Good call on the swing in share price, also as noted this is a more of a long term bet, with many ups and downs, but if all goes will it will be worth the wait, IMO.

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

https://www.sciencedirect.com/science/article/pii/S2274580724005971?via%3Dihub

IMO; ABOS has ENORMOUS POTENTIAL and is RIDICULOUSLY CHEAP!!!

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Link to press release:
https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-announces-journal-prevention-alzheimers

Well; that didn't take long!! Per SEC reporting; 561,000 NEW SHARES were issued to officers and Directors today that vest over 3 years!!

AND, 820,100 TEN year OPTIONS at $1.85 were issued to these same Officers and Directors today. These vest equally over the next 48 months.

I'm also guessing there were probably another batch of shares issued for this past years' service to these same officers. We won't know that until the 10K comes out at the end of March

On Thursday, 5 officers (including our CEO) of Acumen filed 144 Forms to sell an aggregate of 90,630 shares. My guess is that that shares were issued a year ago as a year end bonus to these 5 officers.

ABOS, under $2

There will be more tax loss selling and no rush to get back in as there will be no phase II results for MANY months.

I think this could be a VERY powerful long term investment but it will require a lot of patience which most investors of today's times don't have. Everyone wants to be a trader and buy at the last possible time.

Agree, a good investment at this price, with a potential upside worth the wait. You are probably right on the reason for the dip, did not expect it. Suppose its a good time to buy more at a ridiculous price.

The recent Evercore discussion highlights on a lot of good points, and worth listening to. Looking forward to updates next Q1 on results of current trials, and new trials.

"Video Journal of Dementia (VJDementia) " post ongoing videos on dementia, and has Acumen videos on the p-tau217 assay.

https://www.youtube.com/channel/UCYnoowKy7NI-5Gp58b_tUfA/videos

Obviously an attractive tax loss candidate as there is no meaningful news expected near term and a tax loss seller will have the opportunity to buy back after 31 days.

This is a long term investment with ridiculous upside if the phase II trial is successful. However; you will have to be very patient with this investment.

A marketed competitor, Lecanemab, is going the SC-AI route,

“EISAI COMPLETES ROLLING SUBMISSION TO US FDA FOR LEQEMBI® (LECANEMAB-IRMB) ”

https://media-us.eisai.com/2024-10-31-Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI-R-lecanemab-irmb-Biologics-License-Application-for-Subcutaneous-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimers-Disease-Under-the-Fast-Track-Status

Feeds suspicion Acumen is developing a triple combo, Sabirnetug-hyaluronidase-autoinjectior, with Halozyme.

An upcoming fireside chat might shed light on the next P2 clinical trial for SC sabirnetug….

”UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024, at 1:15 p.m. PT (4:15 p.m. ET).”

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-ubs-global-healthcare

On a side note a short video on the p-TAU-127 biomarker screening presentation has been posted…

https://www.neurologylive.com/view/acumen-pharmaceuticals-phase-2-advancements-ad-screening-todd-feaster-psyd

Which as noted earlier, sub-3 with be history after the presentation.....looking good so far......

The two current competitors….Kisunla and Leqembi

https://alzheimersweekly.com/how-to-choose-between-leqembi-vs-kisunla/

Good article on current and upcoming competitors…

......“Beginning a New Era of Precision Alzheimer’s Therapeutics”

https://www.insideprecisionmedicine.com/topics/translational-research/beginning-a-new-era-of-precision-alzheimers-therapeutics/

Prothena has several up and coming ALS drugs, comment on website gives more incentive for Acumen to develop SC sabirnetug along with an AI.

........Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

.......“Prothena is developing a molecule that we certainly hope will be delivered at home, once monthly, by subcutaneous administration and can be self-administered. I think that from a treatment burden perspective that allows us to start to think about the idea that any patient should have access to these types of approaches, and we think that that’s very important,” said Gene Kinney, PhD, Prothena CEO and president.”

https://www.prothena.com/pipeline/

Suspect days of sub 3 bucks will be history after the presentation later this week.

https://finance.yahoo.com/news/acumen-pharmaceuticals-deliver-breaking-presentation-120000342.html

Very informative article on Amyloid-?.....Update on clinical trial started back in Oct 2016, and still on going...

Acumen is in the right place, right time, right drug, IMO.....

Need to down load the PDF.....

"A Plasma Biomarker Panel for Detecting Early Amyloid-? Accumulation and its Changes in Middle-Aged Cognitively Unimpaired Individuals at Risk for Alzheimer's Disease"

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4986366

https://clinicaltrials.gov/study/NCT02485730?term=NCT02485730&rank=1

Significant comments made in this discussion last week.......

Discussion is very good, best part is little more than 4:00 into discussion Siemers mentions Sabirnetug Efficacy is better and fewer side effects then the competition, Lecanemab , and Donanemab.....Cool......

"UNDERSTANDING ALZHEIMER’S AND THE PATH FORWARD, WITH ERIC SIEMERS, MD"

(Eric Siemers, MD, chief medical officer at Acumen Pharmaceuticals, )

"Early detection of Alzheimer's is vital for effective treatment, according to Eric Siemers, MD, who emphasizes the importance of caregiver support and proactive planning for families navigating the diagnosis."

https://www.theeducatedpatient.com/view/understanding-alzheimer-s-and-the-path-forward-with-eric-siemers-md

Interesting article with some relevance...

Giving more more reason for going the SC route using Halozyme's Enhanze and AI.....

"Smaller vial size for Alzheimer's drug could save Medicare hundreds of millions per year"

"Nearly 6% of Alzheimer's drug lecanemab is discarded, costing Medicare $1,600 per patient per year"

https://www.sciencedaily.com/releases/2024/10/241014210332.htm

ABOS under $3

SP is looking good today, along with volume.....

A lot of news out there on the competition LEQEMBI, and Donanemab, giving insight on Sabirnetug potential.

Interesting news from a couple days on wasted volumes of the competition, giving insight into the cost of the drug and giving yet another reason for a prefilled AI.

https://www.uclahealth.org/news/release/smaller-vial-size-alzheimers-drug-could-save-medicare

"The researchers on the study, published(Link is external) October 14 in the peer-reviewed JAMA Internal Medicine, estimate that Medicare could waste up to $336 million annually due to discarded medication."

“However, we estimate lecanemab waste to be only 5.8%, rendering current policy ineffective, and sounding the bell that further policy changes are likely needed,” he said.

Lonza is on board, and will make a good CDMO partner.

"If The CDMO Shoe Fits, Wear It Now"

"In November of 2022, Acumen entered an agreement with Lonza that granted it a worldwide non-exclusive license to use Lonza’s glutamine synthetase gene expression system to manufacture and commercialize ACU193/sabirnetug."

"Although that predates his joining Acumen (in February of this year), Doherty says there had been an earlier round of work performed with a different set of providers, “but as we announced, we are working with Lonza moving forward.”

https://www.outsourcedpharma.com/doc/if-the-cdmo-shoe-fits-wear-it-now-0001

Another speculative piece of info is the new Director position.

One of the Qualifications is:

"Extensive experience (15+ years) in regulatory affairs within the biopharmaceutical industry; monoclonal antibody experience required; biologics (large molecule) and drug-device combination experience is preferable."

Drug-device is an autoinjector, IMO.

https://theorg.com/org/acumen-pharmaceuticals/jobs/director-cmc-regulatory-b576d02a

Yes, one of these days, but still accumulating so don't want it to move up too fast.

The presentation last week is worth listening to, and doing a thorough review of the PowerPoint info. They did a good job of explaining sabirnetug development and progress. An interesting (and exciting) detail is improvements were measured in a few biomarkers after only 3 doses.

Slide 68 show they are working with Halozyme for SC injection, completed Phase 1, and Phase 2 will start soon. IMO, they will develop an autoinjector for sabirnetug using Holzyme Enhanze and AI. At the end of the Q&A section the speaker mentions the difficulty of developing an AI.

Will be waiting for the current ALTITUDE trial update, a good update will move the SP, and planning on being all in by then.

"Expected Phase 1 subcutaneous topline results 1Q25"

"Expected completion of enrollment of ALTITUDE-AD 1H25"

https://investors.acumenpharm.com/static-files/c6a0d4a6-b7ec-421c-9230-d245ec96f9b4

Add in $2.30s ready to go one of these days .. Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AßOs in AD patients. Soluble AßOs are a highly toxic form of Aß that begin to accumulate before a clinical diagnosis of AD and are an early and persistent trigger of synaptic dysfunction and neurodegeneration. Acumen is developing sabirnetug as a potential next generation antibody treatment for early AD. Acumen is currently enrolling patients in the ALTITUDE sabirnetug -AD study, a Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of intravenous sabirnetug in patients with early AD. Acumen is also evaluating a subcutaneous formulation of sabirnetug in a Phase 1 pharmacokinetic comparison study in healthy volunteers.

The extended collaboration builds upon an existing successful relationship between the two companies, in which Lonza provides DS manufacturing for the Phase 2 clinical supply of sabirnetug. Under the terms of the extended agreement, Lonza will manufacture cGMP DP of sabirnetug for the ongoing and future clinical phases and support the potential commercial launch at its industry-leading state-of-the-art DP manufacturing facility in Visp, Switzerland. Lonza will also provide quality control and stability testing as part of the collaboration.

Peter Droc, Head of Drug Product Services, Lonza, commented: “Our team of experts has extensive experience in supporting the clinical and commercial manufacture of drug products. In line with our strategy to offer an integrated end-to-end offering for biologics manufacturing, we are looking forward to collaborating with Acumen to advance its innovative and promising drug candidate in the clinic and beyond.”

James Doherty, President and Chief Development Officer, Acumen Pharmaceuticals, added: “The extension of our collaboration comes at a time when we’re advancing our clinical programs for sabirnetug with more than 50 Phase 2 sites activated across the U.S., Canada, U.K. and EU. We look forward to continuing our work with Lonza and delivering a potential next-generation treatment for early Alzheimer’s disease.”

About Sabirnetug (ACU193)

Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AßOs), which are a highly toxic and pathogenic form of Aß, relative to Aß monomers and amyloid plaques. Soluble AßOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AßOs, sabirnetug aims to address the hypothesis that soluble AßOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AßOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AßOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.

ABOS under $3

ABOS under $3

ABOS under $4

ABOS under $3

ABOS under $5

ABOS 10Q due 3/26